This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A second discussion on the treatment landscape and the potential of ELREXFIO (elranatamab-bcmm) in patients with multiple myeloma in light of the recent FDA accelerated approval.

Ticker(s): PFE

Who's the expert?

Institution: Cox Health

  • Specializes in hematology, oncology
  • Board certified in hematology, oncology, internal medicine
  • not an expert or investigator in NK cell immune therapy but familiar with it being another vector that is being looked into as it can be off the shelf immunotherapy. 

Interview Goal
discussion potential of ELREXFIO in patients with multiple myeloma

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.